FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

Venture Capital news from FierceBiotech

News

NanoBio looks for Big Pharma partners

Crain's Detroit Business is reporting that NanoBio--a 2008 Fierce 15 company--is close to announcing an $11 Read more...

ProteoStasis secures $45M in first round

Despite a lack of office space or even a complete research team, newcomer ProteoStasis Therapeutics has secured a whopping $45 million in Series A financing. Investors include Boston-based HealthCare Read more...

Anthera garners $19M in new venture funds

Anthera Pharmaceuticals has completed a $19 million venture round and plans to use the funds to advance its work on anti-inflammatory drugs. New investors Caxton Advantage Life Sciences Fund and HBM Read more...

Follica quickly lans $11M second round

Just seven months after raising $5.5 million in its Series A round, Boston-based Follica announced that it Read more...

InterWest closes $650M fund

Life science VC firm InterWest Partners has closed a $650 million fund. The money will be invested in emerging life sciences and information technology investments. The group aims to invest in 25 to Read more...

Bill offers small developers shot at R&D funds

Biotech companies majority-owned by venture groups would once again have a shot at some $2 billion in Small Business Innovation Research awards under compromise legislation advanced in the U.S. Read more...

ESBATech rounds up $22M in second round

Switzerland's ESBATech has garnered $22 million in an extended Series B round. The money goes to expand its pipeline and advance the biotech's work developing antibody fragment therapies. SV Life Read more...

Tetraphase raises $15M for antibiotic work

Massachusetts-based Tetraphase Pharmaceuticals has closed the second tranche of its $25 million Series A financing. The $15 million tranche was funded by existing investors, including Mediphase Read more...

Dimera needs $40M to survive, mount trial

The tiny, Portland-based developer Dimera tells the local Business Journal that the company needs to raise $40 million in order to survive. Backed by the president's personal funds and grants from Read more...
Tags: Venture Capital   Dimera  

Versant closes $500M fund for early-stage research

Versant Ventures has pulled together $500 million to fund life science companies. The investment group says it will target approximately 30-35 medical device, biotech, and pharmaceutical investments Read more...

Press Releases

Resolvyx Pharmaceuticals Raises $25 Million in Series B Financing

Resolvyx Pharmaceuticals Raises $25 Million in Series B Financing 4/22/2008 BEDFORD, Mass. -- Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that it has Read more...

Venture Capital Investment Declines in Q1 2008 According to the MoneyTree Report

Venture Capital Investment Declines in Q1 2008 According to the MoneyTree Report Life Sciences, Semiconductors Have Strong Quarter WASHINGTON, DC--(Marketwire - April 21, 2008) - Venture capitalists Read more...

PRESS RELEASE: PregLem Announces CHF 36 Million Series B Funding

PregLem Announces CHF 36 Million Series B Funding GENEVA -- PregLem, a Swiss specialty biopharmaceutical company focused on the development and commercialization of innovative therapeutic compounds Read more...

PRESS RELEASE: BioVex Closes Second Round of Series E Financing

BioVex Closes Second Round of Series E Financing Second and Final Close Completes $35 Million Financing Woburn, MA, November 15 2007 – BioVex Inc, a clinical stage company developing new Read more...

PRESS RELEASE: Zosano Pharma Announces Funding Close Totaling $90 Million

Zosano Pharma Announces Funding Close Totaling $90 Million FREMONT, Calif. -- Zosano Pharma, Inc., an emerging specialty pharmaceutical company focused on developing better pharmaceutical products Read more...

Get more Venture Capital coverage at: